Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danshen sodium chloride injection is a botanical drug product derived from the roots of *Salvia miltiorrhiza* (Danshen), formulated in a sodium chloride solution for intravenous administration. It is primarily used in China for the treatment of cardiovascular conditions, including coronary artery disease, angina pectoris, and myocardial infarction. The therapeutic profile of the injection is driven by its bioactive constituents, such as salvianolic acids and danshensu, which possess antioxidant, anti-inflammatory, and anti-platelet properties. These components work to improve blood flow, resolve stasis, and protect the myocardium from oxidative stress and ischemia-reperfusion injury. The drug has been evaluated in clinical trials to establish its safety and efficacy in healthy volunteers and patients with cardiovascular distress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on danshen sodium chloride injection.